Results 11 to 20 of about 140,500 (312)

Matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in the diagnosis of colorectal adenoma and cancer patients.

Folia Histochemica et Cytobiologica, 2011
The aim of the study was to assess the importance of the measurement of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of matrix metalloproteinases 2 (TIMP-2) in patients with colorectal cancer (CRC) in relation to clinicopathological features ...
Barbara Mroczko, Magdalena Groblewska, Mariusz Gryko, Bogusław Kędra, Maciej Szmitkowski   +4 more
doaj   +5 more sources

Prognostic Values of Matrix Metalloproteinase-2 and Tissue Inhibitor of Metalloproteinase-2 Expression in Bladder Cancer [PDF]

The Journal of Urology, 1998
Matrix metalloproteinase-2 (MMP-2), which degrades the extracellular matrix or the basement membrane, has an essential role in tumor invasion and metastasis. To evaluate the roles of MMP-2, its inhibitor (tissue inhibitor of metalloproteinase-2 [TIMP-2]), and its activator (membrane-type matrix metalloproteinase-1 [MT1-MMP]) in tumor invasion or as a ...
H, Kanayama, K, Yokota, Y, Kurokawa, Y, Murakami, M, Nishitani, S, Kagawa   +5 more
openaire   +2 more sources

Prognostic Significance of Matrix Metalloproteinase 2 and Tissue Inhibitor of Metalloproteinase 2 Expression in Prostate Cancer [PDF]

Modern Pathology, 2003
Matrix metalloproteinases (MMPs) are proteolytic enzymes capable of degrading the structural support network for normal and malignant cells, promoting neoplastic cell invasion and metastasis. Tissue inhibitors of metalloproteinases (TIMPs) maintain connective tissue integrity by modulating MMP activity.
Jeffrey S, Ross, Prabhjot, Kaur, Christine E, Sheehan, Hugh A G, Fisher, Ronald A, Kaufman, Bhaskar V S, Kallakury   +5 more
openaire   +2 more sources

Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2 [PDF]

Proceedings of the National Academy of Sciences, 2002
Matrix metalloproteinases (MMPs) are a family of multidomain enzymes involved in the physiological degradation of connective tissue, as well as in pathological states such as tumor invasion and arthritis. Apart from transcriptional regulation, MMPs are controlled by proenzyme activation and a class of specific tissue inhibitors of metalloproteinases ...
Ekaterina, Morgunova, Ari, Tuuttila, Ulrich, Bergmann, Karl, Tryggvason   +3 more
openaire   +2 more sources

Kind of Sample as Preanalytical Determinant of Matrix Metalloproteinases 2 and 9 and Tissue Inhibitor of Metalloproteinase 2 in Blood [PDF]

Clinical Chemistry, 1998
Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are interesting new diagnostic tools in oncology, liver diseases, and rheumatoid arthritis (1)(2)(3)(4)(5). However, the preanalytical issue of their determination in blood was only recently shown (6).
Jung, K, Laube, C, Lein, M, Lichtinghagen, R, Tschesche, Harald, Schnorr, D, Loening, SA   +6 more
openaire   +3 more sources

An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy [PDF]

Nephrology Dialysis Transplantation, 2006
High glucose and angiotensin-II (Ang-II) levels are the known important mediators of diabetic nephropathy. However, the effects of these mediators on matrix metalloproteinase-2 (MMP-2) and on tissue inhibitor of metalloproteinase-2 (TIMP-2) in proximal tubule cells have yet to be fully examined within the context of early stage diabetic nephropathy.In ...
Sang Youb, Han, Yi Hwa, Jee, Kum Hyun, Han, Young Sun, Kang, Hyoung Kyu, Kim, Jee Young, Han, Young Sik, Kim, Dae Ryong, Cha   +7 more
openaire   +2 more sources

Serum matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in esophageal cancer patients

Folia Histochemica et Cytobiologica, 2012
The positive expression of MMP-2 and TIMP-2 were found in esophageal cancer (EC) tissue and correlated with cancer stage and clinico-pathological features of tumor and patients' survival. However, little is known about serum levels of those proteins in EC patients. The aim of the present study was to investigate the diagnostic significance of MMP-2 and
Magdalena, Groblewska, Barbara, Mroczko, Miroslaw, Kozlowski, Jacek, Niklinski, Jerzy, Laudanski, Maciej, Szmitkowski   +5 more
openaire   +3 more sources

Matrix metalloproteinases at key junctions in the pathomechanism of stroke [PDF]

, 2011
Matrix metalloproteinases play a crucial role in the remodelling of the extracellular matrix through direct degradation of its structural proteins and control of extracellular signaling.
Amento, Ang, Asahi, Asahi, Barkho, Bergers, Bini, Cao, Cardone, Chinopoulos, Cunningham, Denker, Dong, Fabunmi, Fisher, Frisch, Galis, Galis, Galis, Galis, Gidday, Godin, Gross, Gu, Gu, Gurney, Haas, Haddad, Halliwell, Hamann, Harkness, Herman, Hornig, Hyslop, Itoh, Kumura, Langton, Lapchak, Larsen, Lee, Lelongt, Loftus, Lucivero, Luttun, McQuibban, Meredith, Montaner, Montaner, Nagase, Nagel, Nagy, Nagy, Nikkari, Pagenstecher, Qi, Rajagopalan, Ramos, Rekhter, Rolfe, Romanic, Rosell, Rosenberg, Rosenberg, Rosenberg, Rosenberg, Sarén, Sato, Seo, Shrivastava, Shubayev, Siao, Sole, Sottrup, Sternlicht, Strongin, Sukhova, Suzuki, Suzuki, Svedin, Tsuji, Turner, Van, Vogel, Wang, Wang, Webersinke, Yepes, Ying, Zhang, Zhang, Zhang, Zhao   +91 more
core   +1 more source

Implications of MMP9 for Blood Brain Barrier Disruption and Hemorrhagic Transformation Following Ischemic Stroke. [PDF]

, 2016
Numerous studies have documented increases in matrix metalloproteinases (MMPs), specifically MMP-9 levels following stroke, with such perturbations associated with disruption of the blood brain barrier (BBB), increased risk of hemorrhagic complications ...
Adibhatla, Agrawal, Alcaide, Amantea, Amantea, Anthony, Asahi, Asahi, Asahi, Bajor, Bakowski, Bauer, Benarroch, Burk, Candelario-Jalil, Carbone, Castellanos, Castellanos, Chang, Chesler, Choi, Clark, Clark, Conant, Copin, Cuadrado, Cuadrado, Cunningham, Dejonckheere, Fanjul-Fernández, Fernandez-Patron, Ferry, Fiorelli, Frank R. Sharp, Fujimoto, Fujimura, Fujimura, Gasche, Gasche, Gasche, Gautier, Gidday, Golab, Gu, Gurney, Gürsoy-Ozdemir, Hacke, Harris, Heo, Heo, Horstmann, Hu, Inzitari, Jickling, Justicia, Keck, Kelly, Khandoga, Kim, Kuroiwa, Kurzepa, Lapchak, Lee, Lenglet, Lenglet, Li, Lucivero, Lukes, Lynch, Machado, Maier, Manabe, McCarthy, Moldes, Montaner, Montaner, Montaner, Montaner, Montaner, Montaner, Mun-Bryce, Murata, Nguyen, Ning, Oda, Opdenakker, Orbe, Piccardi, Planas, Ra, Ramos-Fernandez, Ranasinghe, Renée J. Turner, Reynolds, Rivera, Rodrigues, Rodríguez, Rodríguez-Yáñez, Romanic, Rosell, Rosell, Rosell, Rosenberg, Rosenberg, Rosenberg, Rosenberg, Sandoval, Schnoor, Shigemori, Si-Tayeb, Sotgiu, Steadman, Sternlicht, Sumii, Svedin, Tan, Tang, Tsuji, Tsuruoka, Turba, Van den Steen, Vandooren, Vukasovic, Wang, Wang, Wang, Yan, Yang, Yang, Yushchenko, Zhao, Zhao, Zhao, Zozulya   +133 more
core   +3 more sources

Matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression is not regulated by norgestimate or norelgestromin

Gynecological Endocrinology, 2004
Steroid hormones regulate endometrial expression of matrix metalloproteinases (MMPs) and their inhibitors. Synthetic progestins are widely used in oral contraceptives and for hormone replacement therapy. To assess whether the synthetic progestins norgestimate and its derivative norelgestromin (17-deacetylnorgestimate) modulate the expression of MMPs ...
Prifti, S, Lelle, I, Zhong, G, Strowitzki, T, Rabe, T   +4 more
openaire   +3 more sources